OR for each cardiovascular risk score to predict the progression of subclinical atherosclerosis in 124 patients with SLE
| Risk score | OR (95% CI) | P value |
| Model 1 | ||
| SCORE | 1.41 (0.21 to 9.58) | 0.725 |
| mSCORE | 1.87 (0.37 to 9.36) | 0.446 |
| FRS | 3.64 (0.33 to 39.75) | 0.289 |
| mFRS | 3.81 (1.00 to 14.49) | 0.050 |
| QRISK3 | 4.24 (1.30 to 13.78) | 0.016 |
| PCRE | 1.85 (0.08 to 45.23) | 0.706 |
| Globorisk | 2.67 (0.72 to 9.85) | 0.140 |
| PROCAM | 2.56 (0.29 to 22.87) | 0.396 |
| Model 2 | ||
| SCORE | 1.26 (0.20 to 7.97) | 0.803 |
| mSCORE | 1.77 (0.36 to 8.67) | 0.480 |
| FRS | 4.19 (0.48 to 36.32) | 0.193 |
| mFRS | 4.31 (1.36 to 13.64) | 0.013 |
| QRISK3 | 4.33 (1.58 to 11.85) | 0.004 |
| PCRE | 2.11 (0.10 to 42.89) | 0.628 |
| Globorisk | 2.52 (0.79 to 8.15) | 0.123 |
| PROCAM | 3.50 (0.46 to 26.72) | 0.227 |
Model 1 adjusted for: disease duration, SLICC/ACR DI, cumulative glucocorticoid dose, ΒΜΙ, antiphospholipid antibody positivity, presence of plaque at baseline, statin treatment and one single risk score each time.
Model 2 adjusted for: age, antiphospholipid antibody positivity, glucocorticoids cumulative dose and one single risk score each time.
BMI, body mass index; FRS, Framingham Risk Score; mFRS, modified Framingham Risk Score; mSCORE, modified Systematic Coronary Risk Evaluation; PCRE, Pooled Cohort Risk Equation; PROCAM, Prospective Cardiovascular Munster Study Risk Calculator; QRISK3, QRESEARCH Risk Estimator V.3; SCORE, Systematic Coronary Risk Evaluation; SLICC/ACR DI, Systemic Lupus International Collaborative Clinics/American College of Rheumatology Damage Index.